Skip to content
Triangle logo TriangleGet started
← Study library

NCT00217425 · REGISTRY CONDITION SEARCH

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2023-06-18

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with several chemotherapy drugs (combination chemotherapy) works in treating patients with peripheral T-cell lymphoma or natural killer cell neoplasms.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

12-Month Progression-Free Survival (PFS)

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

3-Year Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
INCLUSION CRITERIA: * Diagnosis of peripheral T-cell or natural killer cell neoplasm * Any stage disease allowed * HTLV-positive tumors allowed * At least one objective measurable disease parameter. Abnormal positron emission tomography scans are not considered evidence of measurable disease unless results are confirmed by CT scan or other appropriate imaging techniques * Age 18 and over * ECOG Performance status 0-2 * Absolute neutrophil count ≥ 1,000/mm\^3(500/mm\^3 if due to bone marrow involvement with lymphoma) * Platelet count ≥ 100,000/mm\^3(50,000/mm\^3 if due to bone marrow involvement with lymphoma) * Bilirubin ≤ 2.0 mg/dL (≤ 3 times upper limit of normal \[ULN\] if due to hepatic involvement with lymphoma) * AST ≤ 2 times ULN (5 times ULN if due to hepatic involvement with lymphoma) * PT, INR, and PTT ≤ 1.5 times normal * Creatinine ≤ 2.0 mg/dL * Urinary protein:creatinine ratio ≤ 1 * History of deep venous thrombosis allowed provided patient is on a stable dose of anticoagulants for at least 2 weeks prior to study entry * LVEF ≥ 50% * History of pulmonary embolism allowed provided patient is on a stable dose of anticoagulants for at least 2 weeks prior to study entry * One prior cycle of CHOP for PTCL allowed * More than 4 weeks since prior major invasive surgery or open biopsy * At least 7 days since prior minor surgery. Peripheral lymph node core biopsy, bone marrow biopsy, fine needle aspiration, skin biopsy, or central line placement are not considered minor surgical procedures * More than 7 days since prior and no concurrent anti-platelet drugs (e.g., ticlopidine, clopidogrel, or cilostazol) except aspirin or other nonsteroidal anti-inflammatory drugs * Concurrent anticoagulants allowed provided patient is on a stable dose * INR must be stable for at least 2 weeks prior to study entry * PT/INR and/or PTT must be closely monitored and levels kept within acceptable range for underlying thrombotic disease * Concurrent heparin flush for maintenance of central line patency allowed EXCLUSION CRITERIA: * Anaplastic lymphoma kinase (ALK)-positive T-cell large cell lymphoma. ALK-negative T-cell large cell lymphoma allowed * Cutaneous T-cell lymphoma * History of or current radiographic evidence of CNS metastasis, including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement * Evidence of bleeding diathesis or coagulopathy * Cerebrovascular accident within the past 6 months * Myocardial infarction within the past 6 months * Unstable angina within the past 6 months * New York Heart Association class II-IV congestive heart failure * Uncontrolled hypertension (i.e., systolic blood pressure \[BP\] \> 150 mm Hg or diastolic BP \> 100 mm Hg) * Other clinically significant cardiovascular or peripheral vascular disease * Abdominal fistula within the past 6 months * Gastrointestinal perforation within the past 6 months * Intra-abdominal abscess within the past 6 months * Concurrent major surgery * Pregnant or nursing. Female patients must have negative pregnancy test. Fertile patients must use effective contraception * History of active seizures * Significant traumatic injury within the past 4 weeks * Non-healing ulcer (unless involved with lymphoma) * Bone fracture * Active infection requiring parenteral antibiotics * HIV positivity * Other active malignancy within the past 6 months except carcinoma in situ of the cervix or basal cell carcinoma of the skin
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \[max. 2 mg\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
    intervention Names
    1. Biological: bevacizumab
    2. Drug: cyclophosphamide
    3. Drug: doxorubicin
    4. Drug: prednisone
    5. Drug: vincristine
    label
    Treatment (A-CHOP followed by MA)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (A-CHOP followed by MA)
    description
    A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days. Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus.
    name
    bevacizumab
    other Names
    1. NSC 704865,
    2. RhuMAb VEGF,
    3. Recombinant Humanized Monoclonal Anti-VEGF Antibody.
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Treatment (A-CHOP followed by MA)
    description
    IV infusion per institutional guidelines.
    name
    cyclophosphamide
    other Names
    1. Cytoxan,
    2. Neosar,
    3. CTX,
    4. CPM.
    type
    DRUG
  3. arm Group Labels
    1. Treatment (A-CHOP followed by MA)
    description
    Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
    name
    doxorubicin
    other Names
    1. Adriamycin, Rubex, Adriamycin RDF, Adriamycin PFS, hydroxydaunorubicin,
    2. hydroxydaunomycin, ADR.
    type
    DRUG
  4. arm Group Labels
    1. Treatment (A-CHOP followed by MA)
    description
    Prednisone is taken orally.
    name
    prednisone
    other Names
    1. Deltasone,
    2. Orasone,
    3. Medicorten,
    4. Panasol-S,
    5. Liquid-Pred.
    type
    DRUG
  5. arm Group Labels
    1. Treatment (A-CHOP followed by MA)
    description
    IV push using extravasation precautions.
    name
    vincristine
    other Names
    1. Oncovin,
    2. Vincasar PFS vincristine sulfate,
    3. VCR,
    4. leucocristine,
    5. LCR.
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
46
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    12-month progression-free survival is defined as the probability of patients remaining alive and progression-free at 12 months from study entry.
    measure
    12-Month Progression-Free Survival (PFS)
    time Frame
    Assessed every 3 months the first 2 years from study entry and every 6 months 3-5 years from study entry.
secondary Outcomes
  1. description
    Overall response rate is defined as proportion of patients who achieve complete remission \[CR, unconfirmed CR (CRu) or Functional CR\] or partial remission. Response is assessed using the criteria from the International Workshop to Standardize Criteria for Non-Hodgkin's Lymphoma (Chesen, 1999).
    measure
    Overall Response Rate
    time Frame
    Assessed after cycle 3, cycle 6, and cycle 8 (if given).
  2. description
    3-year overall survival is defined as the probability of patients surviving at 3 years from study entry.
    measure
    3-Year Overall Survival
    time Frame
    Assessed every 3 months the first 2 years from study entry and every 6 months 3-5 years from study entry.
Full study description
brief Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with several chemotherapy drugs (combination chemotherapy) works in treating patients with peripheral T-cell lymphoma or natural killer cell neoplasms.
detailed Description
OBJECTIVES: Primary * Determine the 12-month progression-free survival of patients with peripheral T-cell or natural killer cell neoplasms treated with bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP). Secondary * Determine the overall response rate (complete remission \[CR, unconfirmed CR, or functional CR\] and partial remission) in these patients after courses 3, 6, and 8 of this treatment regimen. * Determine the overall survival of patients treated with this regimen. * Determine the toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive 6-8 cycles of A-CHOP followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \[max. 2 mg\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles. After completion of study treatment, patients are followed every 3 months for 2 years, and then every 6 months for up to 5 years. PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study within 22 months. ACTUAL ACCRUAL: 46
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-456eaabd559e06fa2fc2
      requested nct id
      NCT00217425
      primary nct id
      NCT00217425
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      c6f7083d76b719bb0f82d255e2f01747e6dc7a3b7c5a712ab96ca6e41601db5b
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-456eaabd559e06fa2fc2
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00217425
      occurrences
      1. context exact
        NCT00217425
        end
        11
        exact text
        NCT00217425
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/97/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5163a83159406f89684446348baf5040b13e08bcc9744f6bee1ef25b75cfbc4e

    Preserved source evidence · Not medical advice